Resource Summary Report

Generated by dkNET on Aug 10, 2026

Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) (197G2) (PE Conjugate)

RRID:AB_2728834
Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 14095, RRID:AB_2728834

Antibody Information

URL: http://antibodyregistry.org/AB_2728834

Proper Citation: Cell Signaling Technology Cat# 14095, RRID:AB_2728834

Target Antigen: p44 and p42 MAP Kinase (Erk1 and Erk2) when dually phosphorylated at Thr202 and Tyr204 of Erk1 (Thr185 and Tyr187 of Erk2), and singly phosphorylated at Tyr204

Host Organism: rabbit

Clonality: monoclonal

Comments: Applications: F

Antibody Name: Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) (197G2) (PE Conjugate)

Description: This monoclonal targets p44 and p42 MAP Kinase (Erk1 and Erk2) when dually phosphorylated at Thr202 and Tyr204 of Erk1 (Thr185 and Tyr187 of Erk2), and singly phosphorylated at Tyr204

Target Organism: monkey, rat, mink, pig, mouse, zebrafish, human

Clone ID: 197G2

Antibody ID: AB_2728834

Vendor: Cell Signaling Technology

Catalog Number: 14095

Record Creation Time: 20250819T225806+0000

Record Last Update: 20250820T035229+0000

Ratings and Alerts

No rating or validation information has been found for Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) (197G2) (PE Conjugate).

No alerts have been found for Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) (197G2) (PE Conjugate).

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 3 mentions in open access literature.

Listed below are recent publications. The full list is available at dkNET .

Pham-Danis C, et al. (2025) Restoration of LAT activity improves CAR T??cell sensitivity and persistence in response to antigen-low acute lymphoblastic leukemia. Cancer cell, 43(3), 482.

Chong WP, et al. (2020) The Cytokine IL-17A Limits Th17 Pathogenicity via a Negative Feedback Loop Driven by Autocrine Induction of IL-24. Immunity, 53(2), 384.

Celis-Gutierrez J, et al. (2019) Quantitative Interactomics in Primary T Cells Provides a Rationale for Concomitant PD-1 and BTLA Coinhibitor Blockade in Cancer Immunotherapy. Cell reports, 27(11), 3315.